The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis.

摘要: The Probucol Quantitative Regression Swedish Trial (PQRST) investigated the effect of lipid lowering and antioxidant drug probucol on development atherosclerosis in humans. 303 hypercholesterolemic patients were randomized to receive either or placebo, combination with dietary advice cholestyramine for a three-year period. was not found progression/regression femoral significantly as assessed by quantitative arteriography. To evaluate effectiveness an during study period, detailed analyses performed 42 patients. During trial, probucol-treated (n = 26) had 15% lower total cholesterol (P < 0.01) 35% high density lipoprotein (HDL) 0.0001) compared controls 16). Low (LDL) from treated individuals more resistant oxidation Cu2+ determined lag phase formation conjugated dienes (220 ± 8 vs. 82 7 min (mean S.E)), showed 13 times peroxides, 97% reduction macrophage degradation close 90% less decrease LDL receptor binding following 0.001 all differences). results demonstrate that although provided significant protection against Cu2+-induced oxidative modification LDL, it lacked atherosclerosis. relevance these observations proposed role is discussed.